QCM Cayman’s Ligand Pharmaceuticals LGND Stock Holding History

QCM Cayman’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,251	Closed	-$232K	–	135
2018 Q1	$232K	Buy	+2,251	New	+$223K	0.6%	66

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

QCM Cayman's LGND Position: Q2 2018 in Review

QCM Cayman sold out of Ligand Pharmaceuticals (LGND) in Q2 2018, closing a stake of 2,251 shares — an estimated $232K sold.

QCM Cayman first reported a position in LGND in Q1 2018 and held it in 1 quarter. The position peaked at $232K in Q1 2018. 346 funds tracked by Wall St. Rank hold LGND as of Q2 2018.

QCM Cayman reported no remaining Ligand Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
QCM Cayman sold 2,251 Ligand Pharmaceuticals shares in Q2 2018, an estimated $232K.
QCM Cayman first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 1 quarter.
QCM Cayman's Ligand Pharmaceuticals position peaked at $232K in Q1 2018.
346 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2018.

Based on QCM Cayman's 13F filing for Q2 2018, filed 14 Aug 2018.